Literature DB >> 2871147

Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.

Y Sugiyama, T Fujita, M Matsumoto, K Okamoto, I Imada.   

Abstract

The effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in isolated brain mitochondria from rats and dogs were studied. CV-2619 was easily reduced by canine brain mitochondria in the presence of respiratory substrates. Reduced CV-2619 (2H-CV-2619) was rapidly oxidized through the cytochrome b chain, indicating that the compound functioned simply as an electron carrier of mitochondrial respiratory system. Both nicotinamide adenine dinucleotide (NADH)- and nicotinamide adenine dinucleotide phosphate (NADPH)-dependent lipid peroxidations were examined in canine brain mitochondria in the presence of adenosine diphosphate (ADP) and Fe3+. NADH-cytochrome c reductase activity was sensitive to NADPH-dependent lipid peroxidation. CV-2619 (10(-5)M) strongly inhibited both types of the lipid peroxidation reactions and protected the resultant inactivation of the NADH-cytochrome c reductase activity. Activities of succinate oxidase in rat and canine brain mitochondria were virtually unaffected by CV-2619 and its metabolites (10(-5)-10(-6) M). On the other hand, CV-2619 markedly suppressed the state 3 respiration in glutamate oxidation in a dose dependent manner without any effect on the state 4 respiration and the ADP/O ratio in intact rat brain mitochondria. The inhibitory effect of CV-2619 was also observed in NADH-cytochrome c reductase, but not in NADH-2,6-dichlorophenolindophenol (DCIP) and NADH-ubiquinone reductases in canine brain mitochondria. These facts and results of inhibitor analysis suggest that the action site of CV-2619 is NADH-linked complex I in the mitochondrial respiratory chain and is different from that of inhibitors of oxidative phosphorylation such as rotenone, oligomycin and 2,4-dinitrophenol. Finally, the above findings suggest that CV-2619 acts as an electron carrier in respiratory chains and functions as an antioxidant against membrane damage caused by lipid peroxidation in brain mitochondria. It appears likely that the inhibition of oxygen consumption caused by CV-2619 is related to the effect on non-respiratory systems such as lipid peroxidation which also consumes oxygen.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2871147     DOI: 10.1248/bpb1978.8.1006

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  18 in total

1.  Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of Idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia.

Authors:  Matthias L Jauslin; Silvia Vertuani; Elisa Durini; Lisa Buzzoni; Nunzia Ciliberti; Sara Verdecchia; Paola Palozza; Thomas Meier; Stefano Manfredini
Journal:  Mol Cell Biochem       Date:  2007-05-03       Impact factor: 3.396

Review 2.  [Synthesis and biochemical actions of idebenone and related compounds. Ubiquinone and related compounds, XL].

Authors:  H Morimoto
Journal:  Naturwissenschaften       Date:  1989-05

Review 3.  Idebenone: an emerging therapy for Friedreich ataxia.

Authors:  Thomas Meier; Gunnar Buyse
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

Review 4.  Pharmacotherapy for Friedreich ataxia.

Authors:  Amy Y Tsou; Lisa S Friedman; Robert B Wilson; David R Lynch
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Effect of a ubiquinone-like molecule on oxidative energy metabolism in rat cortical synaptosomes at different ages.

Authors:  D Curti; E Izzo; L Brambilla; G Facchetti; G Sangiovanni; G Brambilla
Journal:  Neurochem Res       Date:  1995-09       Impact factor: 3.996

Review 6.  Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.

Authors:  J C Gillis; P Benefield; D McTavish
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

Review 7.  Therapeutic developments in Friedreich ataxia.

Authors:  Robert B Wilson
Journal:  J Child Neurol       Date:  2012-07-12       Impact factor: 1.987

Review 8.  Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.

Authors:  Daniele Marmolino; Fabio Acquaviva
Journal:  Cerebellum       Date:  2009-01-23       Impact factor: 3.847

9.  Idebenone Ameliorates Rotenone-Induced Parkinson's Disease in Rats Through Decreasing Lipid Peroxidation.

Authors:  Bahattin Avcı; Caner Günaydın; Tolga Güvenç; Canan Kulcu Yavuz; Nilufer Kuruca; S Sirri Bilge
Journal:  Neurochem Res       Date:  2020-11-28       Impact factor: 3.996

10.  Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I.

Authors:  Michael Erb; Barbara Hoffmann-Enger; Holger Deppe; Michael Soeberdt; Roman H Haefeli; Christian Rummey; Achim Feurer; Nuri Gueven
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.